Episodios

  • On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Sarah DeVos Ph.D. Their conversation focuses on:

    The impact of molecular diagnostics on Alzheimer’s researchRecent Alzheimer’s drug approvalsThe future of Alzheimer’s research

    *Small edit on Sarah's background - She did her graduate work at Washington University in St. Louis and a Postdoc at Massachusetts General Hospital*

    Chapters

    00:00 – Introduction

    01:54 – Why Sarah began studying Alzheimer’s

    03:39 – Current tools and needs for future Alzheimer’s diagnostics

    09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics

    14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages?

    16:36 – What is limiting the development of new Alzheimer’s biomarkers?

    17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s

    19:33 – The genetics of Alzheimer’s

    22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology 

    25:54 – Where can proteomics advance Alzheimer’s research?

    31:25 – The role of proteomics in Alzheimer’s animal models

    34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research

    41:39 - Outro

    Resources

    Dominant Inherited Alzheimer’s Network (DIAN) trials research updates

    o   In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease.

    Amyloid plaque reducing clinical trials:

    o   Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease (Haeberlein et al. 2022)

    o   Donanemab in Early Symptomatic Alzheimer Disease - The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023)

    o   Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022)

    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024)

    o   Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease

    Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021)

    o   Review covering a potentially neuro-protective form of tau called “Big tau”

    Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease (Hurst et al. 2023)

    o   Paper linking the NRN1 protein to cognitive resilience in...

  • On this episode of Translating Proteomics, hosts Parag Mallick and Andreas Huhmer of Nautilus Biotechnology discuss the challenges and opportunities of plasma proteomics. Their conversation focuses on:

    ·      Why blood plasma may be a good source of protein biomarkers

    ·      Current methodologies and pitfalls in plasma proteomics

    ·      The path forward for plasma proteomics

    What is Plasma Proteomics?

    For those who are new to this topic, plasma is the liquid portion of the blood distinct from fractions containing red and white blood cells. Given the relatively non-invasive ways physicians can collect patient plasma, and the blood’s intimate association with tissues throughout the body, plasma is potentially an excellent source of protein biomarkers. Yet, it is quite difficult to measure the levels of all plasma proteins because their concentrations span over 12 orders of magnitude. This episode features an in-depth discussion of the ways plasma proteomics efforts have and have not lived up to the promise of biomarker discovery and what we can do to advance plasma biomarker discovery efforts in the future.

    Chapters

    00:00 – 01:01 – Intro

    01:02 – 4:55 – What is the promise of plasma proteomics?

    04:55  – 07:23 – Is the plasma proteome really the best source of biomarkers?

    07:23 – 10:16 – How do proteins get into the blood and what are the implications for biomarker discovery?

    10:16 – 13:59 – Is it clear that proteins are the best candidates for blood biomarkers?

    13:59 – 19:57 – Advances in and the future of comprehensive plasma proteomics

    19:57 – 22:31 – Pros and cons of fractionating the plasma proteome to discover biomarkers

    22:31 – 28:14 – Progress in identifying multiomic plasma biomarkers and the path forward

    28:14 – End – Outro

    Resources

    Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome (Gardner et al. 2022)

    o   Review from focused on the development multiomics liquid biopsies

    Multicompartment modeling of protein shedding kinetics during vascularized tumor growth (Machiraju et al. 2020)

    o   Work from Parag’s Lab investigating tumor protein shedding

    Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor (Frieboes et al. 2015)

    o   Tumor protein shedding work from Parag’s Lab


    Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations (Hori and Gambhir et al. 2011)

    o   Study modeling how much protein could be shed and detected from different size tumors


    The human plasma proteome: history, character, and diagnostic prospects (Anderson and Anderson 2002)

    o   Review discussing...

  • ¿Faltan episodios?

    Pulsa aquí para actualizar resultados

  • Proteins adopt a wide variety of functions depending upon factors like their location in the cell, their modifications, and the biomolecules they interact with. While many of us may have been taught that single genes produce single proteins that have single functions, protein function is far more dynamic than that. In this episode of Translating Proteomics, Nautilus Co-Founder and Chief Scientist Parag Mallick sits down with University of Cambridge Professor and proteomics expert Kathryn Lilley to discuss our evolving understanding of protein function. They cover:

    How they came to realize protein function is more complex than one gene, one enzyme, one functionFactors that give rise to the dynamic complexity of protein function including proteoforms, protein localization, and moonlightingSteps we can take to better understand and teach others about the complexities of protein function
    Research diving into the complexities of protein functionResearch from the Beltrao Lab using bioinformatics techniques to identify functional phosphosites (Ochoa et al. 2020)Work from the Lilley Lab integrating techniques to investigate ome-wide localization of both RNA and protein (Villanueva et al. 2024)Lilley Lab preprint investigated protein localization changes in a cancer cell line as a result of ionizing radiation treatment (Christopher et al. 2024).Collaborative work with the Lundberg Lab mapping subcellular proteomics (Thul et al. 2017).
    Additional protein function resourcesMoonProt - A database for moonlight proteins from Professor Constance Jeffrey's LabTranslating Proteomics Episode 5 - Why the Biology Surrounding Biology's Central Dogma is Wrong
  • In our Translating Proteomics episode titled "Harnessing Proteoforms to Understand Life's Complexity", Parag and Andreas discussed why proteoforms are important in a theoretical sense. In this episode, Parag sits down with Northwestern University Professor and proteoform pioneer, Neil Kelleher to dive deep into the biology of proteoforms. They cover:

    What proteoforms areExamples of the importance of proteoformsThe scale of and technological advances needed to meet the challenges of proteoform biology.
    Some examples of the power of proteoforms covered in this episodeRecent work from Neil's lab showing blood proteoforms can help predict liver transplant success (Melani et al. 2022).Work form Ying Ge's lab showing changes in troponin proteoforms correlate with varying degrees of heart disease (Zhang et al. 2011).The BioTyper - a mass spectrometry-based device that can identify different kinds of microbes.
    Additional proteoform resourcesThe Human Proteoform Atlas webpagePublication describing The Human Proteoform Atlas (Hollas et al. 2022)Publication discussing how many human proteoforms there are (Aebersold et al. 2018)Animation - Proteoform Analysis on the Nautilus Proteome Analysis Platform
  • Despite incredible leaps in our understanding of molecular biology, the majority of drug development efforts still fail, and those that succeed often fail to return investment dollars. Proteomics has the potential to change that by providing high-resolution views of the biochemical drivers of biological function - proteins. In this episode of Translating Proteomics, Parag and Andreas discuss how proteomics can help researchers identify good drug targets, personalize drug development, and advance precision medicine.

    Chapters:

    00:00 - How do we define good drug targets and "druggable" in the age of proteomics

    08:16 - Advancing personalized medicine through proteomics

    10:58 - How proteomics technologies have changed drug development

    15:13 - New abilities next-generation proteomics technologies give us in drug development

    Learn about proteomics and biomarker discovery:

    https://youtu.be/8rcAxHSRGYs?si=kZ0UX42TJ8tWIaSN

    Learn more about proteomics and precision medicine:

    https://youtu.be/bzRlM45agBY?si=eop2XcGLc_oLeiVc

  • Proteins are far more than just the output of genes. They can be modified in myriad ways to produce millions of proteoforms with altered dynamics, localization, and function. For a comprehensive understanding of biology that will propel drug development and biomarker discovery forward, we need to be able to measure proteoforms routinely. In this episode, Parag and Andreas discuss the incredible value that will come from studying proteoforms and describe what it will take to make proteoform measurement a routine part of biology research.

    Chapters:

    00:00 - Introduction to proteoforms

    09:38 - Evidence that proteoforms are important and how we can use proteoform data

    19:28 - Technology advances needed to understand proteoform biology

  • AI might be the biggest buzz word of the decade, but the buzz is warranted in terms of its practical potential in biological research. In this episode of Translating Proteomics, Parag and Andreas discuss some of the early wins for AI in biology, practical ways AI can be applied to biology research in the near term, challenges in that application, and how proteomics researchers in particular can use AI to advance their work.

    Chapters:

    00:00 – Why now is the time to apply AI to biomedicine05:28 – Difficulties and potential solutions when applying AI to biology14:20 – How AI will impact the study of proteins19:34 – Risks of AI in biomedicine
  • From high school biology on up, we're taught the central dogma of biology - that biological information flows from DNA to RNA to proteins. This representation of the central dogma is, however, very much a simplification of its original formulation by Francis Crick and over-applying it can lead us down spurious paths and faulty conclusions. In this episode of Translating Proteomics, Parag and Andreas dive into the real meaning of the central dogma and discuss how modern biology research, including proteomics, shows we must drastically alter the ways we use and interpret the central dogma.

    Chapters:

    00:00 – What is the central dogma and how is it misinterpreted?

    08:06 – Regulation and control in biology

    11:58 – The need for new models in biology

  • Protein biomarkers are proteins measured as indicators of biological processes. People often hope biomarkers will take the form of elevated or decreased amounts of single proteins, but few single protein measurements provide specific and sensitive indications of biological processes. In this episode of Translating Proteomics, Parag and Andreas discuss why it is difficult to find new biomarkers and describe how new techniques can enable the development of multi-protein, multi-time point, and even multiomic biomarkers that have more potential than any single protein measurement.

    Some key points of discussion:

    Biomarkers are difficult to find because of the methods we use to find them and because there is a ton of variability in natural biological systemsMost proteins are biomarkersWe need more proteome-scale data over space and time to find new biomarkers

    Learn more about biomarkers.

    Let us know what you think about the podcast.

  • It's no surprise that biological systems change dramatically over space and time, but we often ignore these dynamics when comparing biological samples. In the latest episode of Translating Proteomics, Parag and Andreas discuss why it's essential to take space and time into account and envision ways we can design experiments that explicitly incorporate spacial and temporal considerations.

    Chapters:

    00:00 - Biological systems as dynamic, adaptive systems

    04:45 - How current experimental designs rarely take space and time into account

    11:54 - The tools necessary to sufficiently measure biology in space and time

    Some key takeaways from the conversation:

    Different biological processes occur at very different time scalesComplex, multiomic interactions can only be understood over time and spaceWe need to properly collect, annotate, and share omics-level data in order to understand the rules that govern complex biology

    Let us know what you think about the podcast.

  • Sure, proteomics may revolutionize precision medicine and biomarker discovery, but did you know it can help make better cheese? Listen to the latest episode of our new series, "Translating Proteomics" featuring Nautilus Co-Founder and Chief Scientist, Parag Mallick, and Nautilus Senior Director of Scientific Affairs and Alliance Management, Andreas Huhmer to learn the many ways we can put the proteome to work as the proteomics revolution begins to bear fruit.

    Let us know what you think about the podcast.

    Learn more about applications of proteomics

    In this episode, Parag mentions work from Matthias Selbach's Lab. Learn more about the Selbach Lab here.

  • The idea to measure the proteome to get a clear understanding of healthy and diseased tissues at the molecular level has been around for many years but has not come to fruition in a broadly accessible and applicable way. In this episode we discuss:

    Why now is the time to make this goal a realityWhy past efforts to broadly leverage proteomics did not work outWhat we've learned from the pastWhat's changed in proteomics and science in general that makes a proteomics breakthrough possible

    Learn more about proteomics

    Let us know what you think about the podcast.